Company profile: Instant Labs
1.1 - Company Overview
Company description
- Provider of a fully-integrated, portable, and affordable real-time polymerase chain reaction (RT-PCR) platform for rapid, accurate pathogen detection, developing and marketing the Hunter Real-Time-PCR system. Focus areas include molecular diagnostic equipment, food safety testing equipment, and food verification testing.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Instant Labs
KSQ Therapeutics
HQ: United States
Website
- Description: Provider of CRISPR-enabled drug discovery and development, offering KSQ-4279, a USP1 inhibitor in Phase 1 for advanced solid tumors targeting DNA damage repair; eTIL autologous cell therapies (KSQ-001, KSQ-004) engineered for enhanced tumor killing in solid tumors; the CRISPRomics platform for target identification in oncology and autoimmune diseases; CRISPR2 guide-pairing technology; and the ExPRESS process for eTIL manufacturing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full KSQ Therapeutics company profile →
Day Zero Diagnostics
HQ: United States
Website
- Description: Provider of whole-genome sequencing–based tools and services for clinical pathogen detection, antimicrobial resistance profiling, and outbreak management, including Blood2Bac to enrich bacterial DNA directly from blood; Keynome ID for species identification; Keynome gAST for resistance profiling; MicrohmDB to support machine learning; and epiXact for pathogen relatedness insights for infection control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Day Zero Diagnostics company profile →
Eligo Bioscience
HQ: France
Website
- Description: Provider of CRISPR/Cas and engineered phage capsid-based antimicrobials and microbiome editing technologies to control bacterial ecosystems in humans and animals. Solutions include the GEM platform for in vivo gene editing, SSAM sequence-specific antimicrobials, FAME for therapeutic gene addition, and capabilities for gene removal, modification, and addition to eradicate resistant pathogens and modulate disease mechanisms.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eligo Bioscience company profile →
4D Path
HQ: United States
Website
- Description: Provider of H&E biopsy/resection image analysis, including 4D Q-Plasia OncoReader Breast (software-as-a-medical-device) for diagnostic accuracy in breast cancer and 4D Q-Plasia OncoReader Pan-Cancer, a cloud platform identifying cancer type, molecular subtypes, grades, and molecular profiles. Also offers automated detection and prognostic evaluation from H&E whole slide images and biomarker profiling and stratification for precision oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 4D Path company profile →
Nightstar Therapeutics
HQ: United Kingdom
Website
- Description: Provider of biopharmaceutical gene therapy research and development focused on retinal dystrophies, aiming to enable treatments for rare conditions caused by single-gene mutations; U.K. startup.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nightstar Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Instant Labs
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Instant Labs
2.2 - Growth funds investing in similar companies to Instant Labs
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Instant Labs
4.2 - Public trading comparable groups for Instant Labs
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →